Your browser doesn't support javascript.
loading
The treatment landscape of advanced angiosarcoma in Asia-A multi-national collaboration from the Asian Sarcoma Consortium.
Chen, Tom Wei-Wu; Pang, Angela; Puhaindran, Mark E; Maw, Myo Myint; Loong, Herbert H; Sriuranpong, Virote; Chang, Chih-Chi; Mingmalairak, Siyamol; Hirose, Takeshi; Endo, Makoto; Kawai, Akira; Farid, Mohamad; Tan, Sze Huey; Goh, Wei Lin; Quek, Richard; Chan, Jeffrey C H; Leung, Alex K C; Ngan, Roger K C.
Afiliación
  • Chen TW; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Pang A; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Puhaindran ME; National University Cancer Institute, Singapore, National University Health System, Singapore City, Singapore.
  • Maw MM; Department of Hand and Reconstructive Microsurgery, National University Hospital, Singapore City, Singapore.
  • Loong HH; Medical Oncology Unit, University of Medicine 1, Yangon, Myanmar.
  • Sriuranpong V; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China.
  • Chang CC; Division of Medical Oncology, Department of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Mingmalairak S; Department of Cancer Administration and Coordination Center, National Taiwan University Hospital, Taipei, Taiwan.
  • Hirose T; Division of Medical Oncology, Department of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Endo M; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Kawai A; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Farid M; Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Tan SH; Division of Medical Oncology, National Cancer Center, Singapore City, Singapore.
  • Goh WL; Division of Clinical Trials and Epidemiological Sciences, National Cancer Center, Singapore City, Singapore.
  • Quek R; Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore City, Singapore.
  • Chan JCH; Division of Medical Oncology, National Cancer Center, Singapore City, Singapore.
  • Leung AKC; Parkway Cancer Centre Singapore, Singapore City, Singapore.
  • Ngan RKC; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China.
Cancer Sci ; 112(3): 1095-1104, 2021 Mar.
Article en En | MEDLINE | ID: mdl-33393133
Angiosarcoma (AS) is a rare disease with a dismal prognosis. The treatment landscape and prognostic factors for advanced AS, including locally advanced, unresectable, and metastatic disease remain elusive. The Asian Sarcoma Consortium is an international collaborative effort to understand the sarcoma treatment landscape in Asia. We undertook a retrospective chart review of AS patients seen in 8 sarcoma academic centers across Asia. Patients with complete clinical, treatment, and follow-up data were enrolled. Overall, 276 advanced AS patients were included into this study; 84 (30%) of the patients had metachronous metastatic AS. The median age was 67 y; primary sites of AS was cutaneous in 55% and visceral in 45% of patients. In total, 143 (52%) patients received at least 1 line of systemic chemotherapy. The most common first-line chemotherapy regimen used was paclitaxel (47.6%) followed by liposomal doxorubicin (19.6%). The median overall survival (OS) was 7.8 mo. Significant prognostic factors for OS included age > 65 (hazard ratio (HR) 1.54, P = .006), male gender (HR 1.39, P = .02), and a cutaneous primary AS site (HR 0.63, P = .004). The median progression-free survival (PFS) for first-line chemotherapy was 3.4 mo. PFS for single vs combination or paclitaxel vs liposomal doxorubicin chemotherapy regimens were comparable. This study provides an insight into the treatment patterns and prognostic factors of advanced AS patients in Asia. Prognosis of advanced AS remains poor. Data from this study serve as a benchmark for future clinical study design.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Protocolos de Quimioterapia Combinada Antineoplásica / Hemangiosarcoma / Recurrencia Local de Neoplasia Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged80 País/Región como asunto: Asia Idioma: En Revista: Cancer Sci Año: 2021 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Protocolos de Quimioterapia Combinada Antineoplásica / Hemangiosarcoma / Recurrencia Local de Neoplasia Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged80 País/Región como asunto: Asia Idioma: En Revista: Cancer Sci Año: 2021 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Reino Unido